CGS Expects Double Digit CAGR In Revenue From Optimax
CGS Expects Double Digit CAGR In Revenue From Optimax
Analysts at CGS project a robust compound annual growth rate (CAGR) of 14.5% for Optimax's revenue from FY23 to FY26, primarily driven by an increase in the number of surgeries. The introduction of the new PRESBYOND machine, which is the first of its kind in Malaysia designed for laser refractive treatment for presbyopia (long-sightedness), is expected to enhance the company's service offerings. This machine allows Optimax to attract a different patient demographic compared to its existing Lasik procedures, which primarily appeal to those under 40.Optimax Holdings has reported a net profit of RM3.8 million for the second quarter of 2024, bringing the total net profit for the first half of the year to RM6.8 million, which constitutes 42% of the company's FY24 forecast and 43% of Bloomberg consensus estimates. Analysts have reiterated an ADD call with a target price of RM0.87, noting that the valuation remains undemanding at -1.0 standard deviation from its average price-to-earnings ratio of 25.3 times for healthcare exposure and growth prospects.
Optimax控股宣佈2024年第二季度淨利潤爲380萬令吉，今年上半年的淨利潤總額爲680萬令吉，佔公司2024財年預測的42%和彭博共識估計的43%。分析師們重申建議增持，並將目標價設定爲0.87令吉，指出估值與其醫療保健暴露和增長前景相比仍不算過高，較其平均市盈率25.3倍低1.0個標準偏差。
The core net profit for Optimax in the second quarter of FY24 was RM3.8 million, reflecting a 1.2% decline year-on-year but a 25% increase quarter-on-quarter. The results are considered in line with expectations, as continued strong earnings momentum is anticipated in the subsequent quarters of FY24 due to the ramp-up of operations at its new ambulatory care centres (ACC). The flat performance year-on-year was attributed to increased staff costs, higher depreciation, and preoperational expenses that outpaced revenue growth.
Optimax在2024財年第二季度的核心淨利潤爲380萬令吉，同比下降1.2%，環比增長25%。該結果被認爲符合預期，預計在2024財年後續季度由於新開設的門診治療中心（ACC）的運營加速，公司的盈利動力將繼續保持強勁。同比平平的業績則歸因於人員成本增加、折舊費用提高和先期業務費用增長超過收入增長。
In the second quarter, Optimax achieved a revenue increase of 14.9% year-on-year, driven by effective marketing strategies, including ongoing promotions on online platforms and contributions from newly established satellite clinics such as Elmina and Taman Melawati. The company's Cambodia ACC and its first aesthetic clinic, Neumax, located in Atria Mall, Selangor, commenced operations in May 2024, while another ACC in Atria Mall started in July. The new ACC in Kota Kinabalu is also slated to open in the third quarter of 2024. These new facilities are expected to positively influence Optimax's revenue and earnings as they ramp up operations.
在第二季度，Optimax實現了14.9%的年增收入增長，受到有效的營銷策略的推動，包括持續在在線平台上進行促銷活動以及來自新設立的衛星診所（如Elmina和Taman Melawati）的貢獻。該公司在2024年5月開設的柬埔寨ACC和第一家位於雪蘭莪艾特利亞購物中心的美容診所Neumax都已投入運營，而艾特利亞購物中心的另一家ACC於7月啓動。位於亞庇市的新ACC也計劃在2024年第三季度開業。這些新設施預計將在增加運營的同時對Optimax的收入和利潤產生積極影響。
Analysts at CGS project a robust compound annual growth rate (CAGR) of 14.5% for Optimax's revenue from FY23 to FY26, primarily driven by an increase in the number of surgeries. The introduction of the new PRESBYOND machine, which is the first of its kind in Malaysia designed for laser refractive treatment for presbyopia (long-sightedness), is expected to enhance the company's service offerings. This machine allows Optimax to attract a different patient demographic compared to its existing Lasik procedures, which primarily appeal to those under 40.
中國銀河分析師預測Optimax的營業收入在2023財年至2026財年間將以14.5%的複合年增長率增長，這主要是由於手術數量的增加。首款專爲老花眼（遠視）激光屈光手術設計的PRESBYOND機器的引入預計將增強公司的服務項目。與現有主要吸引40歲以下人群的Lasik手術相比，這臺機器使Optimax能夠吸引不同的患者群體。
Source: CGS
Title: Look ahead to a stronger 2H24F
來源：中國銀河
標題: 看漲更強勁的2H24F
譯文內容由第三人軟體翻譯。
